Articles related to OBESITY/WEIGHT MANAGEMENT

A review identified 15 reports of Wernicke encephalopathy among patients receiving GLP-1 therapies, most accompanied by poor intake, vomiting, weight loss, or malnutrition, highlighting a rare safety signal without establishing drug-related causality.

In a large multinational target-trial emulation, adults with serious mental illness who initiated GLP-1 receptor agonists experienced lower mortality and cardiovascular event rates than matched patients initiating SGLT2 inhibitors, though residual confounding remains a key limitation.

Nearly one in six pediatric GLP-1 receptor agonist users received a nutritional-deficiency or related diagnosis within one year, while nutrition counseling remained limited and generally occurred months after treatment initiation.

A case report describes duodenal ulcer perforation in a woman receiving tirzepatide for weight loss, occurring shortly after dose escalation, though important confounders prevent conclusions about a causal drug relationship.

Three adults receiving semaglutide or tirzepatide preserved or increased lean soft tissue while losing weight alongside resistance training and protein-focused diets, although the uncontrolled case series cannot determine which strategies produced these outcomes.

A multicenter analysis of adults with biopsy-confirmed MASLD found that roughly one-quarter of cirrhosis cases developed before age 50, with type 2 diabetes and genetic susceptibility associated with earlier progression.